News
SABS
3.070
-0.97%
-0.030
Weekly Report: what happened at SABS last week (1102-1106)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 4d ago
SAB Biotherapeutics (SABS) Q3 2026 Earnings Call Transcript
The Motley Fool · 4d ago
SAB Biotherapeutics Advances SAFEGUARD Enrollment, Supporting Buy Rating and $11 Price Target
TipRanks · 4d ago
SAB Biotherapeutics (SABS) Gets a Buy from Guggenheim
TipRanks · 4d ago
SAB Biotherapeutics reports Q3 EPS (24c), consensus (27c)
TipRanks · 5d ago
SAB Biotherapeutics Q3 2026 Earnings Call Transcript
Benzinga · 5d ago
SAB Biotherapeutics reports Q3 results
Seeking Alpha · 5d ago
Press Release: SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights
Dow Jones · 5d ago
Press Release: SAB BIO Reports Q3 2026 Financial -2-
Dow Jones · 5d ago
Weekly Report: what happened at SABS last week (1026-1030)?
Weekly Report · 11/02 09:45
Weekly Report: what happened at SABS last week (1019-1023)?
Weekly Report · 10/26 09:45
Weekly Report: what happened at SABS last week (1012-1016)?
Weekly Report · 10/19 09:45
SAB Bio Wins FDA Fast Track Status For SAB-142 In Type 1 Diabetes; Stock Up
NASDAQ · 10/13 13:05
SAB Biotherapeutics Wins FDA Fast Track for SAB-142
TipRanks · 10/13 12:59
SAB Biotherapeutics granted Fast Track designation for SAB-142
TipRanks · 10/13 12:40
FDA Provides Fast Track Designation SAB Biotherapeutics' SAB-142 To Treat Stage 3 Type 1 Diabetes
Benzinga · 10/13 12:34
Weekly Report: what happened at SABS last week (1005-1009)?
Weekly Report · 10/12 09:47
Weekly Report: what happened at SABS last week (0928-1002)?
Weekly Report · 10/05 09:47
Weekly Report: what happened at SABS last week (0921-0925)?
Weekly Report · 09/28 09:44
More
Webull provides a variety of real-time SABS stock news. You can receive the latest news about SAB BIOTHERAPEUTICS INC through multiple platforms. This information may help you make smarter investment decisions.
About SABS
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.